Section Arrow
Quote
RNTX.NASDAQ
- Rein Therapeutics Inc
Quotes are at least 15-min delayed:2026/05/11 10:20 EDT
Regular Hours
Last
 1.225
+0.005 (+0.41%)
Day High 
1.23 
Prev. Close
1.22 
1-M High
2.1 
Volume 
81.89K 
Bid
1.22
Ask
1.23
Day Low
1.18 
Open
1.22 
1-M Low
1 
Market Cap 
95.21M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.22 
20-SMA 1.49 
50-SMA 1.37 
52-W High 2.4 
52-W Low 1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.96/-1.33
Enterprise Value
95.21M
Balance Sheet
Book Value Per Share
-0.36
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ENSCEnsysce Biosciences0.3031-0.0471-13.45%-- 
TRAWTraws Pharma Inc2.5+0.32+14.68%3.05PE
MRNAModerna57.265+2.915+5.36%-- 
TNYATenaya Therapeutics1.065+0.065+6.50%-- 
LXRXLexicon Pharmaceuticals2.415+0.415+20.75%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.